Leading the way in Hep C treatment
HARVONI transformed Hep C treatment as the first cure with a simple regimen that’s one pill, once a day for the majority of patients. There’s no interferon, no complex regimens.
Now, HARVONI has been prescribed to over a half million people to cure their Hep C.*
In clinical studies, HARVONI was proven to cure 96–99% of adult patients who had Hep C genotype 1 and no prior treatment with 12 weeks of therapy.† Certain patients were cured with just 8 weeks of therapy.‡ Your Hep C Specialist will determine your length of treatment.
If you don’t have Hep C genotype 1, 4, 5, or 6, learn about another treatment option that may be right for you.
Cure means the Hep C virus is not detected in the blood when measured three months after treatment is completed.
*This information is derived from IMS NPA, IMS NSP™, and IntegriChain® data; data reflect estimated patient starts for HARVONI from 10/2014–3/2018.
†In a study of 865 patients with genotype 1 Hep C and no prior Hep C treatment, with or without cirrhosis (compensated), 99% (210 out of 213) of those who received HARVONI once daily for 12 weeks were cured. In a separate study of 647 patients with GT 1 Hep C, with no prior Hep C treatment and without cirrhosis, 96% (208 out of 216) of those who received HARVONI once daily for 12 weeks were cured.
‡In a study of 647 patients with genotype 1 Hep C, with no prior Hep C treatment and without cirrhosis, 97% (119 out of 123) of those with lower levels of the virus (less than 6 million IU/mL) who received HARVONI once daily for 8 weeks were cured.
These studies did not include patients with advanced cirrhosis (decompensated) or those who have had a liver transplant. Advanced cirrhosis (decompensated) is when the liver is extensively scarred and can no longer do its job effectively.